Making the Invisible, Visible
How often should ILD patients be proactively monitored to support early detection of progressive pulmonary fibrosis?
Patients with ILD should be monitored regularly for progressive pulmonary fibrosis (PPF) in ILD.1 However, patients may want to be tested more frequently. This is usually due to low survival time after PPF identification.2 Watch this video for further insight on how patients may feel about regular monitoring.
Related Content
Early and regular monitoring
Time is of the essence when progressive fibrosing ILD is suspected.2
Increased Interventions for ILDs mortality rates
Early treatment is essential in IPF and could positively impact progression.3-5
Multidisciplinary teams
Multidisciplinary teams can play a central role in ILD diagnosis and management.6
Resources for patients
Helping patients and their loved ones to learn more about their condition.
Providing information and resources to help support and guide patients.
- Chowaniec M, et al. Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management. Reumatologia. 2018;56(4):249–254.
- Cottin V, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076.
- Molina-Molina M, Aburto M, Acosta O, et al. Importance of early diagnosis and treatment in idiopathic pulmonary fibrosis. Exp Rev Resp Med. 2018;12(7):537–539.
- Maher TM, Molina-Molina M, Russell AM, et al. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries. BMC Pulm Med. 2017;17(1):124.
- Robalo-Cordeiro C, Campos P, Carvalho L, et al. Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence. Rev Port Pneumol. 2017;23(5):287–293.
- Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. N Engl J Med. 2020;383:958–968.